CiToxLAB acquires preclinical medical device CRO

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/unification)
(Image: iStock/unification)
CiToxLAB has acquired AccelLAB, a preclinical medical device contract research organization (CRO) as the industry works to align the development of new drugs and medical devices.

According to the company, the acquisition expands its services portfolio to medical devices – with a staff of around 100 people and facilities including operating rooms for cardiac catheterization, state-of-the-art laboratories, a large vivarium, a medical imaging department (scanning and MRI) and clinical pathology and histopathology laboratories.

Dr. Jean-François Le Bigot, Chairman and CEO of CiToxLAB Group said the company identified the preclincical CRO as a “strategic target” to position the group as a “more global services player​.”

Within CiToxLAB Group, AccelLAB allows the convergence process between the development of new drugs and medical devices which represents a new offer to the customers​,” he said.

Drug development and medical devices

Several CROs are preparing for this convergence of drug development and medical devices, as they look to expand offerings into the area – most recently demonstrated with CSSI LifeSciences announcement​ yesterday.

The company told us the launch of its fully integrated medical device contract research organization is a “logical extension​” of its life sciences business.

Additionally, the FDA and EMA recently introduced new guidance and regulations for medical devices and medical device/drug combinations.

Related news

Show more

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars